Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

How The Midwest Was Won: Creating A New Epicenter For Device Innovation And Investment

Executive Summary

Talent, innovation, world-class research institutions, established supply chains, and a lower cost of doing business – what else do you need to launch and grow a device company? Well, capital, for one. Players in the Midwest are working in a variety of ways to draw entrepreneurs and venture money to the region, and their efforts are reaping positive results.

You may also be interested in...



Spinal Diagnostics Companies Bring Precision

The current technologies for diagnosing spinal disease don’t consistently deliver what’s required of any medical diagnostic: good predictive value, high specificity, sensitivity, validity, reproducibility, and safety. This is a gap that several young, innovative companies have set out to fill.

Device Trends To Watch In 2013

The prospective medical device tax, the continuing decline of venture investing, pricing challenges, austerity measures in Europe, and other headwinds continued to push against the medtech industry in 2012. But emerging clinical and geographic markets, along with an active M&A market, are providing the industry with some momentum going into 2013.

Cleveland Clinic Innovations – Creating A Global Innovation Engine

At a time when venture capital dollars are scarce and US-based innovation is threatened, Cleveland Clinic Innovations, with its novel GCIC cardiovascular project, is bringing critical mass and a new direction to an inherently unwieldy process.

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

MT035579

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel